Scientific References - Publications

QPS Austria Neuropharmacology

QPS encourages its scientists to publish and disseminate the results of their high quality research which is mostly done in close collaboration with our clients.


The following articles are hyperlinked to the original journal article or an abstract of the article:

Correction: Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease.

Clemensson EKH, Clemensson LE, Fabry B, Flunkert S, Riess O, Wronski R, Nguyen HP.

PLoS One. 2019 Mar 7;14(3):e0213755. doi: 10.1371/journal.pone.0213755. eCollection 2019.

Hepatic and neuronal phenotype of NPC1−/− mice

Estibaliz Santiago-Mujica, Stefanie Flunkert, Roland Rabl, Joerg Neddens, Tina Loeffler, Birgit Hutter-Paier

Heliyon. 2019 Mar 14;5(3):e01293. doi: 10.1016/j.heliyon.2019.e01293

Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humans

Grabner GF, Fawzy N, Pribasnig M, Trieb M, Taschler U, Holzer M, Schweiger M, Wolinski H, Kolb D, Horvath A, Breinbauer R, Ruelicke T, Rabl R, Lass A, Stadlbauer V, Hutter-Paier B, Stauber RE, Fickert P, Zechner R, Marsche G, Eichmann TO, Zimmermann R.

J Lipid Res. 2019 Mar 20. pii: jlr.M093351. doi: 10.1194/jlr.M093351.

BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains.
Causevic M, Dominko K, Malnar M, Vidatic L, Cermak S, Pigoni M, Kuhn PH, Colombo A, Havas D, Flunkert S, McDonald J, Gunnersen JM, Hutter-Paier B, Tahirovic S, Windisch M, Krainc D, Lichtenthaler SF, Hecimovic S. PLOS ONE. 2018 Jul 6;13(7):e0200344. doi: 10.1371/journal.pone.0200344.

Phosphorylation of different tau sites during progression of Alzheimer’s disease.
Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B. Acta Neuropathol Commun. 2018 Jun 29;6(1):52. doi: 10.1186/s40478-018-0557-6.

mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms.
Scherz B, Rabl R, Flunkert S, Rohler S, Neddens J, Taub N, Temmel M, Panzenboeck U, Niederkofler V, Zimmermann R, Hutter-Paier B. PLOS ONE. 2018 May 22;13(5):e0197674. doi: 10.1371/journal.pone.0197674.

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease.
Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D. Molecules. 2017 Oct 10;22(10). pii: E1693. doi: 10.3390/molecules22101693

SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer’s disease.
Brunner D, Flunkert S, Neddens J, Duller S, Scopes DIC, Treherne JM, Hutter-Paier B. Neurosci Lett. 2017 Sep 13. pii: S0304-3940(17)30770-X. doi: 10.1016/j.neulet.2017.09.028. [Epub ahead of print].

Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Collier TJ, Srivastava KR, Justman C, Grammatopoulous T, Hutter-Paier B, Prokesch M, Havas D, Rochet JC, Liu F, Jock K, de Oliveira P, Stirtz GL, Dettmer U, Sortwell CE, Feany MB, Lansbury P, Lapidus L, Paumier KL. Neurobiol Dis. 2017 Jul 12. pii: S0969-9961(17)30159-6. doi: 10.1016/j.nbd.2017.07.007. [Epub ahead of print].

Glutaminyl Cyclase Inhibitor PQ912 improves cognition in mouse models of Alzheimer’s disease – studies on relation to effective target occupancy.
Hoffmann T, Meyer A, Heiser U, Kurat S, Bohme L, Kleinschmidt M, Buhring KU, Hutter-Paier B, Farcher M, Demuth HU, Lues I, Schilling S. J Pharmacol Exp Ther. 2017 Apr 26. pii: jpet.117.240614. doi: 10.1124/jpet.117.240614.

Early and progressive microstructural brain changes in mice overexpressing human α-Synuclein detected by diffusion kurtosis imaging.
Khairnar A, Ruda-Kucerova J, Szabó N, Drazanova E, Arab A, Hutter-Paier B, Neddens J, Latta P, Starcuk Z Jr, Rektorova I. Brain Behav Immun. 2017 Mar;61:197-208. doi: 10.1016/j.bbi.2016.11.027.

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R, Breitschaedel C, Flunkert S, Duller S Amschl D, Neddens J, Niederkofler V, Rockenstein E, Masliah E, Roemer H, Hutter-Paier B. BMC Neurosci. 2017 Jan 31;18(1):22. doi: 10.1186/s12868-017-0341-8.

Quantitative evaluation of orofacial motor function in mice: The pasta gnawing test, a voluntary and stress-free behavior test.
Rabl RHorvath A, Breitschaedel C, Flunkert S, Roemer H, Hutter-Paier BJ Neurosci Methods. 2016 Dec 1;274:125-130. doi: 10.1016/j.jneumeth.2016.10.006.

Decreased Plasma Aβ in Hyperlipidemic APPSL Transgenic Mice is Associated with BBB Dysfunction.
Löffler T, Flunkert S, Temmel M, Hutter-Paier BFront Neurosci. 2016 Jun 1;10:232. doi: 10.3389/fnins.2016.00232.

Brain cortical cholesterol metabolism is highly affected by human APP overexpression in mice.
Löffler T, Schweinzer C, Flunkert S, Sántha M, Windisch M, Steyrer E, Hutter-Paier BMol Cell Neurosci. 2016 Jul;74:34-41. doi: 10.1016/j.mcn.2016.03.004.

Late-stage α-synuclein accumulation in TNWT-61 mouse model of Parkinson’s disease detected by diffusion kurtosis imaging.
Khairnar A, Ruda-Kucerova J, Drazanova E, Szabó N, Latta P, Arab A, Hutter-Paier B, Havas D, Windisch M, Sulcova A, Starcuk Z Jr, Király A, Rektorova I. J Neurochem. 2015 Dec 19. doi: 10.1111/jnc.13500.

Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson’s Disease: A Pilot Study.
Khairnar A, Latta P, Drazanova E, Ruda-Kucerova J, Szabó N, Arab A, Hutter-Paier B, Havas D, Windisch M, Sulcova A, Starcuk Z Jr, Rektorova I. Neurotox Res. 2015 Nov;28(4):281-9. doi: 10.1007/s12640-015-9537-9.

Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer’s Disease on Amyloid Precursor Protein Metabolism and Pathology.
Krassnig S, Schweinzer C, Taub N, Havas D, Auer E, Flunkert S, Schreibmayer W, Hutter-Paier B, Windisch M. Neurodegener Dis. 2015;15(4):243-57. doi: 10.1159/000430952 Jun 25.

Long-term treatment of aged Long Evans rats with a dietary supplement containing neuroprotective peptides (N-PEP-12) to prevent brain aging: effects of three months daily treatment by oral gavage.
Hutter-Paier B, Reininger-Gutmann B, Wronski R, Doppler E, Moessler H. J Med Life. 2015 Apr-Jun;8(2):207-12.

Multigram Synthesis and in Vivo Efficacy Studies of a Novel Multitarget Anti-Alzheimer’s Compound
Sola I, Viayna E, Gómez T, Galdeano C, Cassina M, Camps P, Romeo M, Diomede L, Salmona M, Franco P, Schaeffer M, Colantuono D, Robin D, Brunner D, Taub N, Hutter-Paier B, Muñoz-Torrero D. Molecules. 2015 Mar 10;20(3):4492-515. doi: 10.3390/molecules20034492.

L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model
Daschil N, Kniewallner KM, Obermair GJ, Hutter-Paier B, Windisch M, Marksteiner J, Humpel C. Neurobiol Aging. 2015 Mar;36(3):1333-41. doi: 10.1016/j.neurobiolaging.2014.12.027.

Alzheimer’s Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits
Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM. PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898.

Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer’s disease
Tina Löffler, Stefanie Flunkert, Daniel Havas, Cornelia Schweinzer, Marni Uger, Manfred Windisch, Ernst Steyrer, Birgit Hutter-PaierJournal of Neuroinflammation. DOI: 10.1186/1742-2094-11-84 (May, 2014)

Tracking of Magnetite Labeled Nanoparticles in the Rat Brain Using MRI
Naira P. Martínez Vera, Reinhold Schmidt, Klaus Langer, Iavor Zlatev, Robert Wronski, Ewald Auer, Daniel Havas, Manfred Windisch, Hagen von Briesen, Sylvia Wagner, Julia Stab, Motti Deutsch, Claus Pietrzik, Franz Fazekas, Stefan Ropele PLoS One. March 14, 2014.

Increased Efflux of Amyloid-β Peptides through the Blood-Brain Barrier by Muscarinic Acetylcholine Receptor Inhibition Reduces Pathological Phenotypes in Mouse Models of Brain Amyloidosis.
Paganetti P, Antoniello K, Devraj K, Toni N, Kieran D, Madani R, Pihlgren M, Adolfsson O, Froestl W, Schrattenholz A, Liebner S, Havas D, Windisch M, Cirrito JR, Pfeifer A, Muhs A. J Alzheimers Dis. 2013 Sep 26.

The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon.
Rosini M, Simoni E, Bartolini M, Soriano E, Marco-Contelles J, Andrisano V, Monti B, Windisch M, Hutter-Paier B, McClymont DW, Mellor IR, Bolognesi ML. ChemMedChem. 2013 Aug;8(8):1276-81. doi: 10.1002/cmdc.201300263. Epub 2013 Jul 3.

CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-β plaques in an Alzheimer’s disease mouse model.
LDaschil N, Obermair GJ, Flucher BE, Stefanova N, Hutter-Paier B, Windisch M, Humpel C, Marksteiner J. J Alzheimers Dis. 2013;37(2):439-51. doi: 10.3233/JAD-130560.

Commentary to the recently published review “Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer’s disease” by Li, Evrahimi and Schluesener. Ageing Res. Rev. 2013 Jan;12(1):116-40.
Windisch M, Flunkert S, Havas D, Hutter-Paier B. Ageing Res Rev. 2013 Jul 10;12(4):852-854. doi: 10.1016/j.arr.2013.06.006.

Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice.
Löffler T, Flunkert S, Havas D, Sántha M, Hutter-Paier B, Steyrer E, Windisch M. Neurobiol Aging. 2013 May 2

CSF biomarker variability in the Alzheimer’s Association quality control program.
Alzheimer’s Association QC Program Work Group (QPS Austria GmbH collaborator: Duller S.) Alzheimers Dement. 2013 May;9(3):251-61. doi: 10.1016/j.jalz.2013.01.010.

Non-selective calcium channel blocker bepridil decreases secondary pathology in mice after photothrombotic cortical lesion.
Lipsanen A, Flunkert S, Kuptsova K, Hiltunen M, Windisch M, Hutter-Paier B, Jolkkonen J.
PLoS One. 2013;8(3):e60235. doi: 10.1371/journal.pone.0060235. Epub 2013 Mar 26.

In Vivo and Ex Vivo Imaging of Amyloid-ß Cascade Aggregates with a Pronucleon™ Peptide.
Nyborg AC, Moll JR, Wegrzyn RD, Havas D, Hutter-Paier B, Feuerstein G., Rudolph AS. J Alzheimers Dis. 2013 Jan 15.

Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model.
Amschl D, Neddens J, Havas D, Flunkert S, Rabl R, Römer H, Rockenstein E, Masliah E, Windisch M, Hutter-Paier B. BMC Neurosci. 2013 Jan 9;14:6. doi: 10.1186/1471-2202-14-6

Modulation of gamma-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.
Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller MJ, Spaulding D, Yang Z, Hodgdon H, Nolan S, Wen M, Costa D, Blain JF, Freeman E, De Strooper B, Vulsteke V, Scrocchi L, Zetterberg H, Portelius E, Hutter-Paier B, Havas D, Ahlijanian M, Flood D, Leventhal L, Shapiro G, Patzke H, Chesworth R, Koenig G. Mol Neurodegener. 2012 Dec 18;7(1):61

Elevated Levels of Soluble Total and Hyperphosphorylated Tau Result in Early Behavioral Deficits and Distinct Changes in Brain Pathology in a New Tau Transgenic Mouse Model.
Flunkert S, Hierzer M, Löffler T, Rabl R, Neddens J, Duller S, Schofield EL, Ward MA, Posch M, Jungwirth H, Windisch M, Hutter-Paier B. Neurodegener Dis. 2012 Jul 10

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS. Nature.2012 May  2;485(7400):651-5. doi: 10.1038/nature11060

Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer’s disease drug candidates.
Löffler T, Flunkert S, Taub N, Schofield EL, Ward MA, Windisch M, Hutter-Paier B. J MolNeurosci.2012 May;47(1):192-203. doi: 10.1007/s12031-012-9716-6.

A Longitudinal Study of Behavioral Deficits in an AβPP Transgenic Mouse Model of Alzheimer’s Disease.
Havas D, Hutter-Paier B, Ubhi K, Rockenstein E, Crailsheim K, Masliah E, Windisch M. J Alzheimers Dis. 2011;25(2):231-43. doi: 10.3233/JAD-2011-101866

The gamma-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer’s disease.
Lanzillotta A, Sarnico I, Benarese M, Branca C, Baiguera C, Hutter-Paier B, Windisch M, Spano P, Imbimbo BP, Pizzi M. J Mol Neurosci. 2011 Sep;45(1):22-31. doi: 10.1007/s12031-010-9482-2. Epub 2010 Dec 22.

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers.Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line.
Alzheimer’s Association QC Program Work Group (QPS Austria GmbH co-author: Duller S.) Alzheimers Dement. 2011 Jul;7(4):386-395.e6. doi: 10.1016/j.jalz.2011.05.2243.

Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line.
Czvitkovich S, Duller S, Mathiesen E, Lorenzoni K, Imbimbo BP, Hutter-Paier B, Windisch M, Wronski R. J Mol Neurosci. 2011 Mar;43(3):257-67

Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease.
Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Alzheimers Res Ther. 2011 Jan 6;3(1):1. doi: 10.1186/alzrt59

The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.
Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, Frosch MP, Hutter-Paier B, Windisch M, Kovacs DM. J Neuropathol Exp Neurol. 2010 Aug.

Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer’s disease model.
Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, Sundstrom LE, Costello AJ, Hovens CM J Clin Neurosci. 2010 Aug;17(8):1025-33.

L-type calcium channel CaV 1.2 in transgenic mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations.
Willis M, Kaufmann WA, Wietzorrek G, Hutter-Paier B, Moosmang S, Humpel C, Hofmann F, Windisch M, Knaus HG, Marksteiner J. J Alzheimers Dis. 2010;20(4):1167-80.

Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.
Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA. J Pharmacol Exp Ther. 2010 Jun;333(3):748-57.

Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway.
Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM. FASEB J. 2009 Nov;23(11):3819-28.

CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer’s disease.
Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M. Br J Pharmacol. 2009 Mar;156(6):982-93.

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s disease-like pathology.
Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S. Nat Med. 2008 Oct;14(10):1106-11.

Chromogranin B and Secretogranin II in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations and in Alzheimer patients.
Willis M, Prokesch M, Hutter-Paier B, Windisch M, Stridsberg M, Mahata SK, Kirchmair R, Wietzorrek G, Knaus HG, Jellinger K, Humpel C, Marksteiner J. J Alzheimers Dis. 2008 Mar;13(2):123-35.

The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?
Windisch M, Wolf H, Hutter-Paier B, Wronski R. Neurodegener Dis. 2008;5(3-4):218-21.

Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
Windisch M, Wolf HJ, Hutter-Paier B, Wronski R. Curr Alzheimer Res. 2007 Dec;4(5):556-61.

Localization and expression of substance P in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations.
Willis M, Hutter-Paier B, Wietzorrek G, Windisch M, Humpel C, Knaus HG, Marksteiner J. Brain Res. 2007 Apr 27;1143:199-207.

Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer’s disease.
Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M. Vaccine. 2007 Apr 20;25(16):3041-52.

Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window.
Schauer E, Wronski R, Patockova J, Moessler H, Doppler E, Hutter-Paier B, Windisch M. J Neural Transm. 2006 Jul;113(7):855-68.

A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication.
Riley C, Hutter-Paier B, Windisch M, Doppler E, Moessler H, Wronski R. J Neural Transm. 2006 Jan;113(1):103-10.

N-PEP-12–a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions.
Windisch M, Hutter-Paier B, Grygar E, Doppler E, Moessler H. J Neural Transm. 2005 Oct;112(10):1331-43.

The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease.
Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM. Neuron. 2004 Oct 14;44(2):227-38.

Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
Windisch M, Hutter-Paier B, Schreiner E, Wronski R. J Mol Neurosci. 2004;24(1):155-65.

EFRH-phage immunization of Alzheimer’s disease animal model improves behavioral performance in Morris water maze trials.
Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, Hutter-Paier B, Solomon B. J Mol Neurosci. 2004;24(1):105-13.

The protective effect of ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition.
Windisch M, Hutter-Paier B, Jerkovic L, Imbimbo B, Villetti G. Neurosci Lett. 2003 May 8;341(3):181-4.

Characterization of proliferation and differentiation of EGF-responsive striatal and septal precursor cells.
Castillo L, Martínez L, Grygar E, Hutter-Paier B. Int J Dev Neurosci. 2003 Feb;21(1):41-7.

In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death.
Gutmann B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R. Neurotox Res. 2002 Feb;4(1):59-65.

Vitamin E binding protein afamin protects neuronal cells in vitro.
Heiser M, Hutter-Paier B, Jerkovic L, Pfragner R, Windisch M, Becker-André M, Dieplinger H. J Neural Transm Suppl. 2002;(62):337-45.

Current drugs and future hopes in the treatment of Alzheimer’s disease.
Windisch M, Hutter-Paier B, Schreiner E. J Neural Transm Suppl. 2002;(62):149-64.

Development of a new treatment for Alzheimer’s disease and Parkinson’s disease using anti-aggregatory beta-synuclein-derived peptides.
Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. J Mol Neurosci. 2002 Aug-Oct;19(1-2):63-9.

Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons.
Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. J Neural Transm. 2001;108(4):459-73.

Effects of NaCN and ionomycin on neuronal viability and on the abundance of microtubule-associated proteins MAP1, MAP2, and tau in isolated chick cortical neurons.
Hutter-Paier B, Grygar E, Loibner M, Skofitsch G, Windisch M. Cell Tissue Res. 2000 Oct;302(1):39-47.

A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons.
Wronski R, Kronawetter S, Hutter-Paier B, Crailsheim K, Windisch M. J Neural Transm Suppl. 2000;59:263-72.

Epidermal growth factor-responsive precursors with similar properties isolated from embryonic rat septum and striatum.
Castillo L, Grygar E, Hutter-Paier B. Rev Neurol. 2000 Jul 1-15;31(1):26-31. 

Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer’s disease.
Wronski R, Tompa P, Hutter-Paier B, Crailsheim K, Friedrich P, Windisch M. J Neural Transm. 2000;107(2):145-57.